PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25802231-1	2015	Ibrutinib (Imbruvica ) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton"s tyrosine kinase (BTK) that inhibits B-cell antigen receptor signalling downstream of BTK.	ibrutinib	0-9	Bruton tyrosine kinase	Homo sapiens	95-119	
25802231-1	2015	Ibrutinib (Imbruvica ) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton"s tyrosine kinase (BTK) that inhibits B-cell antigen receptor signalling downstream of BTK.	ibrutinib	0-9	Bruton tyrosine kinase	Homo sapiens	121-124	
25802231-1	2015	Ibrutinib (Imbruvica ) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton"s tyrosine kinase (BTK) that inhibits B-cell antigen receptor signalling downstream of BTK.	ibrutinib	0-9	Bruton tyrosine kinase	Homo sapiens	189-192	
25802231-1	2015	Ibrutinib (Imbruvica ) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton"s tyrosine kinase (BTK) that inhibits B-cell antigen receptor signalling downstream of BTK.	ibrutinib	11-20	Bruton tyrosine kinase	Homo sapiens	95-119	
25802231-1	2015	Ibrutinib (Imbruvica ) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton"s tyrosine kinase (BTK) that inhibits B-cell antigen receptor signalling downstream of BTK.	ibrutinib	11-20	Bruton tyrosine kinase	Homo sapiens	121-124	
25802231-1	2015	Ibrutinib (Imbruvica ) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton"s tyrosine kinase (BTK) that inhibits B-cell antigen receptor signalling downstream of BTK.	ibrutinib	11-20	Bruton tyrosine kinase	Homo sapiens	189-192